文献速递心外重症与机械循环支持

高危心脏手术作为终末期心衰替代移植或机械支持的选项

High-risk cardiac surgery as an alternative to transplant or mechanical support in patients with end-stage heart failure.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-03-21

本研究回顾2002至2012年间133例左室射血分数<20%且VO2 max<14 mL/min/m2、初诊转诊接受高级治疗但改行常规手术的终末期心衰患者,院内死亡12%,5年和10年生存率分别为72%±4%和39%±8%;倾向调整后,适合移植者长期生存与移植相当,不适合移植者与左室辅助装置相当。

要点

  • 终末期心衰高危患者行常规心脏手术院内死亡12%,5年生存72%±4%。
  • 适合移植者常规手术长期生存与移植相当(HR 1.48,P=.34)。
  • 不适合移植者常规手术生存与左室辅助装置相当(HR 0.49,P=.21)。

核心结论

  • 尽管围术期风险高,适合高级治疗的高度选择终末期心衰患者行常规手术中期生存可接受,或可作为一种替代选择。

研究设计与样本

  • 回顾性队列研究,纳入2002至2012年左室射血分数<20%且VO2 max<14 mL/min/m2、初诊转诊接受高级治疗但改行常规手术的终末期心衰患者133例,其中适合移植68例、不适合移植65例。

主要发现

  • 5年和10年 actuarial 生存率分别为72%±4%和39%±8%。
  • 非缺血性病因被确定为晚期死亡预测因素。
  • 倾向调整模型中,适合移植者常规手术长期生存与移植相当(HR 1.48,95%CI 0.66-3.2,P=.34)。
  • 不适合移植者常规手术生存与左室辅助装置治疗相当(HR 0.49,95%CI 0.16-1.50,P=.21)。

临床怎么用

  • 对于高度选择的终末期心衰患者,在移植和心室辅助装置可及性有限时,可考虑常规心脏手术作为替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although the results of cardiac surgery in patients with poor left ventricular function have been widely published, the outcomes in patients with end-stage heart failure who meet criteria for advanced therapies are not well investigated. As access to transplantation and ventricular assist device therapy remains limited, we explored the possibility of conventional surgery as an alternative option for highly selected patients with end-stage heart failure. METHODS: We identified patients with left ventricular ejection fraction <20% and VO2 max <14 mL/min/m2, who were initially referred for advanced therapies but were instead offered a conventional procedure from 2002 to 2012. We examined the short- and midterm outcomes and compared survival with that after our advanced therapies in the same era. RESULTS: A total of 133 patients were identified; 68 were deemed to be transplant-eligible, whereas 65 were transplant-ineligible. Seventy-nine percent were in New York Heart Association class III/IV. In-hospital mortality was 12%. Actuarial survival at 5 and 10 years was 72% ± 4% and 39% ± 8%, respectively. Nonischemic etiology was identified as a predictor of late mortality. In the propensity-adjusted model, our transplant-eligible patients had comparable long-term survival to our transplantation patients (HR 1.48 [95% confidence interval, 0.66-3.2], P = .34), whereas the survival in our transplant-ineligible subset was comparable to the survival after our left ventricular assist device therapy (HR 0.49 [95% confidence interval, 0.16-1.50], P = .21). CONCLUSIONS: Despite high perioperative risk, the midterm survival after conventional surgery in patients eligible for advanced therapies seems to be acceptable and may be an alternative option for highly selected patients with end-stage heart failure.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kawajiri H, Manlhiot C, Ross H, et al. High-risk cardiac surgery as an alternative to transplant or mechanical support in patients with end-stage heart failure. J Thorac Cardiovasc Surg. 2017. PMID: 28495061. doi:10.1016/j.jtcvs.2017.03.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。